NEUROCRINE BIOSCIENCES, INC. (NBIX) FY2026 Q2 P&L / Income Statement

NEUROCRINE BIOSCIENCES, INC. (NBIX) FY2026 Q2 P&L / Income Statement

Income statement for 2026-04-01 through 2026-06-30. View: Product and service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Total revenues

959,000,000 US dollars

Cost of revenue (calculated)

23,200,000 US dollars

Gross profit (calculated)

935,800,000 US dollars

Operating expenses (calculated)

784,300,000 US dollars

Operating income

151,500,000 US dollars

Total other income, net

10,700,000 US dollars

Income before provision for income taxes

162,200,000 US dollars

Provision for income taxes

17,800,000 US dollars

Net income

144,400,000 US dollars

Net product sales

954,300,000 US dollars

Collaboration revenues

4,700,000 US dollars

Cost of revenues, excluding amortization of acquired intangible assets

23,200,000 US dollars

Research and development

326,700,000 US dollars

Acquired in-process research and development

1,500,000 US dollars

Selling, general, and administrative

439,700,000 US dollars

Amortization of acquired intangible assets

16,400,000 US dollars

Gain on sale of business, net of transaction costs

0 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.